184 related articles for article (PubMed ID: 26199309)
1. Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies.
Vaduganathan M; Butler J; Pitt B; Gheorghiade M
Circ Heart Fail; 2015 Jul; 8(4):826-31. PubMed ID: 26199309
[No Abstract] [Full Text] [Related]
2. MY APPROACH to the patient with heart failure and improved ejection fraction
Cohn JN
Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
[No Abstract] [Full Text] [Related]
3. Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction.
Samson R; Le Jemtel TH
J Am Heart Assoc; 2021 Jun; 10(12):e021120. PubMed ID: 34056916
[TBL] [Abstract][Full Text] [Related]
4. Targeting heart failure with preserved ejection fraction: current status and future prospects.
Kanwar M; Walter C; Clarke M; Patarroyo-Aponte M
Vasc Health Risk Manag; 2016; 12():129-41. PubMed ID: 27143907
[TBL] [Abstract][Full Text] [Related]
5. [Diastolic heart failure. Pathophysiology, diagnosis and therapy].
von Scheidt W
Med Klin (Munich); 1996 Jan; 91(1):28-35. PubMed ID: 8839198
[No Abstract] [Full Text] [Related]
6. Management of chronic congestive heart failure: Part I--General introduction to treatment.
Kayser SR
Prog Cardiovasc Nurs; 1994; 9(1):39-42. PubMed ID: 8058693
[No Abstract] [Full Text] [Related]
7. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
8. Heartbeat: Is there any effective therapy for heart failure with preserved ejection fraction?
Otto CM
Heart; 2018 Mar; 104(5):361-362. PubMed ID: 29440452
[No Abstract] [Full Text] [Related]
9. Drugs for chronic heart failure.
Med Lett Drugs Ther; 2021 Jun; 63(1626):89-96. PubMed ID: 34181628
[No Abstract] [Full Text] [Related]
10. Therapeutic approaches affecting diastolic ventricular function.
Warren SE; Grossman W
Herz; 1991 Feb; 16(1):33-45. PubMed ID: 2026382
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A1 receptor antagonists at a fork in the road.
Givertz MM
Circ Heart Fail; 2009 Nov; 2(6):519-22. PubMed ID: 19919975
[No Abstract] [Full Text] [Related]
12. Comparison chart: Some drugs for HFrEF.
Med Lett Drugs Ther; 2021 Jun; 63(1626):e1-e14. PubMed ID: 34181629
[No Abstract] [Full Text] [Related]
13. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Thanikachalam S; Manchanda SC
Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
[TBL] [Abstract][Full Text] [Related]
14. New therapeutics for chronic heart failure.
Mann DL; Deswal A; Bozkurt B; Torre-Amione G
Annu Rev Med; 2002; 53():59-74. PubMed ID: 11818463
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.
Pinilla-Vera M; Hahn VS; Kass DA
Circ Res; 2019 May; 124(11):1618-1632. PubMed ID: 31120818
[TBL] [Abstract][Full Text] [Related]
16. Surrogate end points in heart failure trials.
Gheorghiade M; Adams KF; Gattis WA; Teerlink JR; Orlandi C; O'Connor CM
Am Heart J; 2003 Feb; 145(2 Suppl):S67-70. PubMed ID: 12594457
[No Abstract] [Full Text] [Related]
17. Principles of drug therapy in heart failure.
Dey SK; Poflee VW
Natl Med J India; 1995; 8(2):73-8. PubMed ID: 7735067
[No Abstract] [Full Text] [Related]
18. A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing-induced model of canine heart failure.
Shirasaka T; Miyagawa S; Fukushima S; Saito A; Shiozaki M; Kawaguchi N; Matsuura N; Nakatani S; Sakai Y; Daimon T; Okita Y; Sawa Y
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):413-21. PubMed ID: 23541854
[TBL] [Abstract][Full Text] [Related]
19. Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy.
Nanas JN; Tsagalou EP; Nanas SN; Terrovitis JV; Tsolakis EJ; Toumanidis S; Papazoglou PD; Alexopoulos GP; Kanakakis J; Anastasiou-Nana MI
Int J Cardiol; 2006 Apr; 108(2):237-43. PubMed ID: 16183152
[TBL] [Abstract][Full Text] [Related]
20. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
